Abstract Previous official clinical practice guidelines (CPGs) for epilepsy were based on expert opinions and developed by the Epilepsy Study Group of the Spanish Society of Neurology (GE-SEN).
Introduction
Epilepsy refers to a heterogeneous array of highly prevalent illnesses, and it is regarded as one of the most common reasons for neurological consultation. Epilepsy may be defined as a brain disorder characterised by a long-term predisposition to epileptic seizures (ES), and by the neurobiological, cognitive, psychological, and social consequences of that disorder. Diagnosis must be preceded by at least one ES. This is one of the diseases with the greatest impact on patients' quality of life.
The Epilepsy Study Group of the Spanish Society of Neurology (GE-SEN) has published two previous editions of the official guidelines for the diagnosis and treatment of epilepsy. These guidelines were fundamentally based on expert opinion. The current guidelines, drawn up during 2012, are based on the scientific method, which uses confirmed evidence to formulate recommendations.
This study group comprises 47 epilepsy experts, including neurologists, neurophysiologists, neuroradiologists, and paediatric neurologists. The Guidelines were coordinated by five editors under a general director.
Recommendations for searching and selecting applicable scientific evidence are described below. Prospective cohort studies in a representative population with masked outcome assessment and meeting all criteria from (a) to (e).
Prospective controlled clinical trials with masked outcome assessment in a representative population, but not meeting one of the criteria from (a) to (e). Level 3 All other controlled trials in a representative population in which outcome assessment was independent from the treatment administered. Level 4 Uncontrolled trials, case series, case reports, or expert opinions.
Grades of recommendation
Grade A Recommendation definitively effective, ineffective, or dangerous. Requires at least one conclusive level 1 study or two consistent level 2 studies. Grade B Recommendation likely to be effective, ineffective, or dangerous. Requires at least one conclusive level 2 study or several consistent level 3 studies. Grade C Recommendation that may be effective, ineffective, or dangerous. Requires at least two consistent level 3 studies.
GE-SEN
Recommendation potentially effective, ineffective, or dangerous. This recommendation does not meet minimum requirements for a grade C, but it reflects consensus among contributors to the clinical practice guidelines.
5. Where scientific evidence was lacking, we followed the general instructions in CPGs issued by other medical societies considering that absence of proof should not be considered proof of inefficacy, that is, 'absence of evidence is not evidence of absence.' In such cases, the recommendation is graded by consensus of the medical society itself. In our case, we assigned the recommendation based on consensus of the GE-SEN.
The Guidelines contain a total of 193 recommendations, some of which are expressed as tables or action algorithms. Epilepsy's pathophysiology is unknown, and so is the cause in some cases. Approval of new antiepileptic drugs (AEDs) rests more on administrative than on clinical criteria. The result of this situation is that scientific evidence remains scarce for all areas of epilepsy. This being the case, 57% of the recommendations in these guidelines stem from consensus between authors and editors and not from scientific evidence. They are therefore expressed as GE-SEN recommendations.
In these guidelines, the terminology and classification systems for ES are those established by the Commission on Classification and Terminology of the International League Against Epilepsy in 1989. This is the dominant practice among the sources we reviewed to create these guidelines. 2 These guidelines were shown to be a good reference tool for clinical practice in neurological consults, emergency departments, and primary care centres during 2013.
The full version of this consensus statement can be viewed on the SEN's webpage, and the journal Neurología is publishing excerpts on epilepsy treatment under the following titles: -Emergencies in epilepsy and ES. -Pharmacological treatment of epilepsy (two articles). -Drug-resistant epilepsy. Non-pharmacological treatments.
Emergencies in epilepsy and ES

Introduction
ES account for about 1% of all emergency department visits. These cases can be categorised as follows 3 :
1. Patients whose seizure is associated with signs or symptoms of acute, systemic, or CNS disease. This type is known as provoked seizure (PS) (or acute symptomatic seizure), and its treatment requires resolving the underlying cause as well as achieving seizure control. Due to their poor prognosis, these conditions require immediate and appropriate treatment.
Classifying symptomatic ES by temporal relationship with the cause
Symptomatic ES are those that arise due to brain insult. There are two types: PS and remote symptomatic seizures (RSS). Provoked or acute symptomatic seizures are those directly caused by, or occurring soon after, a precipitating factor. This factor may be metabolic, toxic, structural, infectious, or inflammatory, and it causes an acute brain event (Table 2) . Remote symptomatic ES are caused by preexisting static or progressive brain lesions. They may appear as isolated events or else recur (epilepsy).
The current International Classification of Epileptic Syndromes 4 places PS among the conditions presenting with ES, but not considered to be epilepsy proper. PS do not require long-term antiepileptic treatment, although shortterm treatment may be necessary until the acute condition has resolved.
Scientific evidence for pharmacological treatment of acute symptomatic seizures -Carbamazepine, phenobarbital (PB), phenytoin (PHT), and valproic acid (VPA), the classic AEDs, are effective for preventing PS in cases of severe traumatic brain injury. PHT effectively prevents PS after craniotomy. 5, 6 Level of evidence 1.
-Classic AEDs effectively prevent PS due to traumatic brain injury or craniotomy, contrast material, malaria, or alcohol withdrawal syndrome. They do not prevent RSS or future development of epilepsy due to these causes. 5, 6 Level 1. -Benzodiazepines (BZD) are effective for preventing PS due to alcohol withdrawal. 5 
Patients with an initial tonic-clonic seizure of undetermined cause
Most patients who visit the emergency department due to ES have experienced an initial generalised tonic-clonic seizure (GTCS) whose cause cannot be determined (Fig. 1 ). Figure 1 Diagnostic and therapeutic algorithm for use after an initial generalised tonic-clonic seizure (GTCS).
Scientific evidence on treating an initial GTCS
Unfavourable changes in progression of previously diagnosed epilepsy are characterised by either increase in habitual critical frequency or AED intolerance. Emergency action algorithm for this type of clinical situation is shown in Fig. 2 .
Patients with clustered or prolonged seizures constitute different types of SE. Status epilepticus is a seizure lasting more than 30 minutes, or a sequence of seizures repeated over more than 30 minutes during which time the patient does not recover the baseline neurological state. 9 There are as many types of SE as there are seizure types. The most common classification system for SE is shown in Fig. 3 .
Clinical experience and video-EEG monitoring show that a convulsive seizure that continues beyond 5 minutes gives rise to convulsive SE. Mortality is higher in cases of SE lasting more than 30 minutes.
The literature lists different definitions and classifications of SE for use in clinical practice and treatment. 7, 10 • Convulsive tonic-clonic SE:
-A generalised, continuous convulsive seizure lasting 5 minutes or longer. -Two or more generalised convulsive seizures presenting without the patient regaining consciousness between seizures. 
Anticonvulsant treatment Initial convulsive SE episode
Clinical response to convulsive SE should initially entail checking vital signs, followed by providing anticonvulsant treatment and treating the cause or other associated problems (Fig. 4) . Most CPGs recommend intravenous (IV) administration of the BZD drugs lorazepam (LZP) or diazepam (DZP) as the first line of treatment for all types of SE. 7, 11 Scientific evidence for initial treatment of convulsive SE -LZP and DZP are effective for treating convulsive SE. 14 Loading dose, route of administration, and duration of effect vary for different types of BZD (Table 3) .
Established convulsive SE
If the initial BZD treatment, including a second dose, fails to control convulsive SE, a second-line AED must be administered (Table 4) . 
16
-Most CPGs recommend using LZP (4 mg IV) or DZP (10 mg IV) followed by PHT (18 mg/kg IV) or PB (20 mg/kg IV).
7,11
Level 4. -Treatment with VPA, LEV, or LCM is indicated in cases of RSE or when PHT is contraindicated, as an alternative to IV PB. 17, 18 Level 3. LEV and LCM are not authorised as treatments for SE.
Several randomised clinical trials are currently being carried out to compare the efficacy of PHT, fosphenytoin, VPA, and LEV. 19 Treatment for the cause of seizures, if known, should be administered simultaneously with anticonvulsants. Systemic complications of SE (fever, metabolic disorders, rhabdomyolysis, etc.) should also be treated at the same time (Table 5) .
RSE
There is no consensus on a definition of RSE. The medical literature defines RSE as a seizure lasting more than 60 minutes, or failure of two appropriately employed and properly dosed second-line AEDs.
Steps in treating RSE are as follows: superior to non-barbiturates (propofol, MDZ) for inducing a medical coma. 10, 11, 20 Level 4. The choice of treatment depends on associated comorbidities, pharmacokinetics, and adverse effects. If RSE persists after 24 hours of starting anaesthetic treatment, or if SE recurs with reduction or withdrawal of anaesthesia (a clinical state called 'super-refractory' SE by some authors), other types of non-anaesthetic treatment should be attempted. These include magnesium sulphate, pyridoxine (in children), steroids, immunoglobulins, plasmapheresis, hypothermia, ketogenic diet, electroconvulsive therapy, neurosurgery for lesion-induced SE, and vagus nerve stimulation; treatment sequences vary depending on the cause and according to different authors. 20 Level 4.
NCSE
This definition is based on absence of manifest motor activity with an indicative EEG pattern. If there is a clinical suspicion, the diagnosis is confirmed by EEG. Lack of unified EEG terminology makes it more difficult to classify cases of NCSE. Most authors use electroclinical data to classify NCSE into two groups: with and without coma/stupor.
The group without coma/stupor is further subdivided into SE with generalised onset (absence SE: typical, atypical, or myoclonic), focal onset (NCSE with or without altered consciousness, aphasia, etc.), and unknown origin (autonomic NCSE). 21 There is no high-level evidence regarding which treatment to choose for each type.
For non-hospitalised patients with a prolonged history of confusional states, experts recommend treatment with BZD, preferably by the oral route. 7 Treatment for patients in coma following a convulsive SE episode (subtle NCSE) resembles that for RSE cases.
Critical activity can be seen on the EEG trace in 20% to 30% of the cases in which the patient is comatose and his/her situation is critical due to a wide range of serious causes (anoxic brain injury after cardiac arrest, head trauma, severe intoxication, etc.). The underlying cause, which determines prognosis, has to be treated in these cases, and non-sedating AEDs must be added to the treatment regimen. 12 We have listed recommendations for a variety of clinical situations that may be observed in the emergency department (Table 6 ).
